Long-Term Survival Rate of Transcatheter Aortic Valve Replacement
Caitlin Hoeing, Samrah Ansari, Sophie Pickering, Alexandra Reph, James K. Wu, MD.
Lehigh Valley Health Network, Allentown, PA, USA.
Transcatheter aortic valve replacement (TAVR) is a very prevalent procedure for high and moderate risk patients with severe aortic stenosis. Previous studies have found that patients on dialysis are at higher risk for decreased survival rates post-TAVR. This study seeks to evaluate the survival rates of hemodialytic, chronic kidney disease (CKD), and standard TAVR patients.
This study is a single-center retrospective review of all TAVR patients from 2012-2019 at a local health network. The in-house database containing medical records and personal information on patients was utilized to assess patient outcomes. A unique database was created to record and analyze data through descriptive statistics.
A cohort of 913 patients over 7 years was assessed. Out of 639 patients without renal dysfunction, 149 patients died (23.36%) with an average survival time of 689.59 days. 42.31% of patients on dialysis died, with an average survival time of 569.55 days. There were 271 patients with CKD pre-TAVR, and 25.18% died with an average survival time of 484.08 days. The average length of stay in the hospital was 4.5 days.
|Factor||Number of eventsa||Number censoredb||Total sample size|
Table 1: TAVR Patient Mortality Summary
Factor 0: Control Factor 1: CKD Factor 2: Dialysis
Patients coincidingly on dialysis are at higher risk for the TAVR procedure. There is a significant decrease in survival rates for dialytic patients compared to CKD and standard patients. When comparing the CKD population with the regular patients, there is no significant difference in mortality rate. Long-term survival rates for non-dialysis patients illustrate success for TAVR.
Back to 2019 Program